Acute conjunctivitis in the course of seasonal and perennial allergic eye inflammation. Inflammation associated with conjunctival irritation due to the use of contact lenses, sunlight, cigarette smoke, contact with water in the swimming pool, etc.
Composition:
1 ml of solution contains: 1 mg diphenhydramine hydrochloride and 0.33 mg naphazoline nitrate. The preparation contains benzalkonium chloride.
Action:
A combined preparation containing an antihistaminic drug - diphenhydramine and α-adrenomimetic - naphazoline. Diphenhydramine is an H receptor antagonist1. By competitive blocking of the histamine H receptor1 inhibits allergic symptoms, especially those associated with the release of histamine, such as increased permeability and vasodilation. Naphazoline stimulates vascular α-adrenergic receptors and when used topically, it leads to contraction of the dilated blood vessels and a reduction of symptoms associated with inflammation. The full topical effect of nafazoline appears after 5 minutes of application. The effect lasts for 6-8 hours.
Contraindications:
Hypersensitivity to diphenhydramine hydrochloride or nafazoline nitrate or to an excipient. Glaucoma with a narrow angle. Hypersensitivity to adrenomimetic agents.
Precautions:
Due to the content in benzalkonium chloride, people wearing soft (hydrophilic) contact lenses should remove them before instillation and wait at least 15 minutes before re-insertion. Benzalkonium chloride may cause eye irritation and change the color of contact lenses. The drug should not be used in the case of chronic conjunctivitis, it can be used for a short period of exacerbation of a chronic disease. Caution should be exercised in patients with hypertension, cardiac arrhythmias, hypersensitivity to sympathomimetic amines, e.g. hyperthyroidism and prostatic hyperplasia and the elderly. These patients should be informed that in the event of any general symptoms suggesting that naphazoline may have been systemically absorbed, discontinue use. It is not recommended for infants and children up to 6 years of age due to unpredictable and potentially dangerous side effects. If symptoms of eye irritation or pain persists for more than 72 hours, the patient should be discontinued and the patient should be informed. The use of the drug for more than 5 days or more than every 3 hours is not recommended because of the risk of rebound, secondary to the severity of edema and increased secretion, as well as the possibility of permanent changes in the epithelium.
Pregnancy and lactation:
drug can be used during pregnancy only if in the doctor's opinion the benefit for the mother outweighs the potential risk to the fetus. There are no data on the penetration of the active components of the drug into human milk. In breast-feeding women, the drug should be used with caution.
Side effects:
Transient symptoms such as burning, pruritus, conjunctival hyperaemia, eye pain, blurred vision are most common. A case of corneal opacification was described in a patient who instilled the drug into the conjunctival sac for 7 days at least 10 times a day; after discontinuation of the drug, the turbidity disappeared. Rarely observed: drowsiness, palpitation, hypertension, headache and dizziness, nausea, increased intraocular pressure. Long-term use may lead to local changes in the epithelium associated with its hypoxia (worsening prognosis), as well as to the so-called the "from reflection" effect.
Dosage:
Adults and children over 6 years: 1-2 drops into the conjunctival sac if necessary every 6-8 h. The drug should not be used for more than 3 to 5 days.
(C)
